• Depleting White Blood Cells Improves Response to CAR T-cell Therapy in Heavily Treated Patients, Trial Shows
  • Calquence Shows Durable Responses in Relapsed or Refractory Mantle Cell Lymphoma, Phase 2 Trial Shows
  • Truxima Shows Safety, Efficacy Comparable to Rituxan in Advanced Follicular Lymphoma
  • Follow-up Trial Results Reinforce Yescarta as Relapsed Non-Hodgkin’s Lymphoma Therapy
  • Size Matters: Height May Heighten Risk Factor for Certain Cancers, Study Finds
  • Generon Set to Begin Phase 1 Trial of A-319 in Patients With B-cell Cancers in China
  • Young People Give Me Hope
  • 5F9-Rituxan Combo Eliminates Tumors in One-third of DLBCL, Follicular Lymphoma Patients
  • Truxima Becomes First Biosimilar to Rituxan Approved in US for Non-Hodgkin’s Lymphoma
  • Poteligeo Approved in Europe for 2 Forms of Cutaneous T-cell Lymphoma
  • Surrender to the Seasons of Your Life
  • First Patient Dosed in Phase 3 Trial of BeiGene’s Zanubrutinib for Hard-to-Treat Leukemia, Lymphoma